New eczema drug IBI3033 enters first human tests
NCT ID NCT07549984
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing an experimental drug called IBI3033 in 16 adults with moderate-to-severe atopic dermatitis (eczema). The main goal is to check if the drug is safe and how the body processes it. Participants will receive either IBI3033 or a placebo injection over 12 weeks, with follow-up for 4 more weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IBI3033 (an experimental drug given as an injection under the skin)
What this could lead to
If successful, this early study could pave the way for a new treatment option to ease symptoms of moderate-to-severe eczema.
What could go wrong
This is a very small, early-stage (Phase 1) trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hangzhou First People's Hospital
Hangzhou, Hangzhou, 310006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••